By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit, and

Key Statistics

Ownership: Public

Web Site: Genomic Health, Inc.
Symbol: GHDX


Company News
Genomic Health, Inc. (GHDX) Release: CMS Increases Final Pricing Determination For Oncotype DX Breast Cancer Test To Previously Established Rate Of $3,416 10/7/2015 6:54:01 AM
Genomic Health, Inc. (GHDX) Responds To Flawed CMS Gap-Fill Pricing For Oncotype DX Breast Cancer Test 9/28/2015 12:20:29 PM
Genomic Health, Inc. (GHDX) Release: TAILORx Trial Finds 99 Percent Of Women With Low Oncotype DX Recurrence Score Are Free Of Breast Cancer Recurrence After Five Years Of Hormone Therapy Alone 9/28/2015 6:54:49 AM
Genomic Health, Inc. (GHDX) Release: Two Large International Studies Provide Additional Prospective Data Reinforcing The Ability Of Oncotype DX To Accurately Predict Clinical Outcomes In Early-Stage Breast Cancer Patients 9/28/2015 6:11:44 AM
Genomic Health, Inc. (GHDX) Release: Multiple Oncotype DX Outcomes Studies, Including Results From NCI-sponsored TAILORx Breast Cancer Trial, To Be Presented At 2015 European Cancer Congress 9/11/2015 8:05:46 AM
Genomic Health, Inc. (GHDX) Release: Breast Cancer Research And Treatment Publishes Oncotype DXDCIS Score Study Conducted In Canada 8/20/2015 6:27:48 AM
Genomic Health, Inc. (GHDX)'s Oncotype DX®Prostate Cancer Test Receives Medicare Coverage 8/17/2015 6:29:21 AM
Genomic Health, Inc. (GHDX) Announces Second Quarter 2015 Financial Results And Reports Record International And Prostate Cancer Tests Delivered 8/5/2015 7:33:31 AM
Genomic Health, Inc. (GHDX) Release: Urology Practice Publishes Study Showing Oncotype DX Increases Use Of Active Surveillance In Prostate Cancer Patients By 56 Percent 7/31/2015 9:47:00 AM
Genomic Health, Inc. (GHDX) To Announce Second Quarter 2015 Financial Results And Host Conference Call On Tuesday, August 4, 2015 7/29/2015 10:09:54 AM